Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology

被引：0

作者：

Hayashi, Toshinobu ^{[1
]}

Yamamoto, Shun ^{[2
]}

Miyata, Yoshiharu ^{[3
]}

Takeda, Masayuki ^{[4
]}

Abe, Masakazu ^{[5
]}

Wada, Makoto ^{[6
]}

Iino, Keiko ^{[7
]}

Akechi, Tatsuo ^{[8
]}

Imamura, Chiyo K. ^{[9
]}

Okuyama, Ayako ^{[10
]}

Ozawa, Keiko ^{[11
]}

Kim, Yong-Il ^{[12
]}

Sasaki, Hidenori ^{[13
]}

Satomi, Eriko ^{[14
]}

Tanaka, Ryuhei ^{[15
]}

Nakajima, Takako Eguchi ^{[16
]}

Nakamura, Naoki ^{[17
]}

Nishimura, Junichi ^{[18
]}

Noda, Mayumi ^{[19
]}

Hayashi, Kazumi ^{[20
]}

Higashi, Takahiro ^{[21
]}

Boku, Narikazu ^{[22
]}

Matsumoto, Koji ^{[23
]}

Matsumoto, Yoko ^{[24
]}

Okita, Kenji ^{[25
]}

Yamamoto, Nobuyuki ^{[26
]}

Aogi, Kenjiro ^{[27
]}

Iihara, Hirotoshi ^{[28
]}

机构：

[1] Fukuoka Univ, Fac Pharmaceut Sci, Dept Emergency & Disaster Med Pharm, 8-19-1,Nanakuma,Jonan Ku, Fukuoka, Japan

[2] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan

[3] Kobe Univ, Dept Artificial Intelligence & Digital Hlth Sci, Grad Sch Med, 7-1-48 Minatojimaminamimachi,Chuo Ku, Kobe, Japan

[4] Nara Med Univ, Dept Epidemiol, 840 Shijo Cho, Kashihara, 6348521, Japan

[5] Hamamatsu Univ Sch Med, Dept Surg, 1-20-1 Handayama,Chuo Ku, Hamamatsu, Shizuoka 4313192, Japan

[6] Osaka Int Canc Inst, Dept Hematol, 3-1-69 Chuo Ku, Osaka, Osaka 5418567, Japan

[7] Natl Coll Nursing, Dept Adult Nursing, 1-2-1,Umezono, Kiyose, Tokyo 2048575, Japan

[8] Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat & Cognit Behav Med, 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya 4678601, Japan

[9] Showa Univ, Adv Canc Translat Res Inst, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428555, Japan

[10] St Lukes Int Univ, Grad Sch Nursing Sci, 10-1 Akashi Cho,Chuo ku, Tokyo 1040044, Japan

[11] Natl Canc Ctr, Inst Canc Control, Div Survivorship, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[12] Yodogawa Christians Hosp, Div Med Oncol, 1-7-50 Kunijima,Higasiyodogawa Ku, Osaka, Osaka 5330024, Japan

[13] Fukuoka Univ, Div Med Oncol Hematol & Infect Dis, 7-45-1,Nanakuma,Jonan Ku, Fukuoka 8140180, Japan

[14] Natl Canc Ctr, Dept Palliat Med, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[15] Saitama Med Univ, Int Med Ctr, Dept Pediat Hematol & Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan

[16] Kyoto Univ, Grad Sch Med, Grad Sch Med, 54 Kawahara Cho,Shogoin,Sakyo ku, Kyoto 6068507, Japan

[17] St Marianna Univ, Dept Microbiol, 2-16-1,Sugao, Miyamae, Kawasaki 2168511, Japan

[18] Osaka Int Canc Inst, Dept Gastroenterol Surg, 3-1-69, Osaka 5418567, Japan

[19] Nonprofit Org Sasaeau KaiAlpha, 518-7 Kawado Cho,Chuo Ku, Chiba, Chiba 2600802, Japan

[20] Jikei Univ, Sch Med, Sch Med, Tokyo, Japan

[21] Univ Tokyo, Dept Hlth Serv Res, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan

[22] Univ Tokyo, Inst Med Sci Hosp, Dept Oncol & Gen Med, 4-6-1 Shiroganedai,Minato ku, Tokyo 1088639, Japan

[23] Hyogo Canc Ctr, Div Diagnost Radiol, 13-70 Kitaoji Cho, Akashi, Hyogo 6730021, Japan

[24] Nonprofit Org Ehime Canc Support Orange No Kai, 3-8-24 Furukawaminami, Matsuyama, Ehime 7900943, Japan

[25] Otaru Ekisaikai Hosp, Dept Surg, 1-4-1 Inaho, Otaru, Hokkaido 0470032, Japan

[26] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama, 6418509, Japan

[27] Natl Hosp Org Shikoku Canc Ctr, Dept Breast Oncol, 160 Kou,Minamiumemoto Machi, Matsuyama, Ehime 7910280, Japan

[28] Gifu Univ Hosp, Dept Pharm, 1-1 Yanagido, Gifu 5011194, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 29卷 / 11期

关键词：

Antiemetics; Carboplatin; Chemotherapy-induced nausea and vomiting; Moderately emetogenic chemotherapy; Neurokinin-1 receptor antagonist; Systematic review and meta-analysis; DOUBLE-BLIND; BROAD RANGE; PHASE-II; APREPITANT; PREVENTION; EFFICACY; CANCER; DEXAMETHASONE; FOSAPREPITANT; PALONOSETRON;

D O I：

10.1007/s10147-024-02623-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundChemotherapy-induced nausea and vomiting (CINV) commonly affects patient quality of life and the overall effectiveness of chemotherapy. This study aimed to evaluate whether adding neurokinin-1 receptor antagonists (NK1RAs) to 5-hydroxytryptamine-3 receptor antagonists (5-HT3RAs) and corticosteroids provides clinically meaningful benefits in preventing CINV in patients receiving moderately emetogenic chemotherapy (MEC).MethodsWe conducted a systematic review of PubMed, Cochrane Library, and Ichushi-Web to identify clinical studies evaluating NK1RAs combined with 5-HT3RAs and dexamethasone for managing CINV in MEC. The endpoints were complete response (CR), complete control (CC), total control (TC), adverse events, and costs. The data were analyzed using a random effects model.ResultsFrom 142 articles identified, 15 randomized controlled trials (RCTs), involving 4,405 patients, were included in the meta-analysis. Approximately 60% of the patients received carboplatin (CBDCA)-based chemotherapy. The meta-analysis showed that triplet antiemetic prophylaxis with NK1RA was significantly more effective for achieving CR than doublet prophylaxis in each phase. Regarding CC, the triplet antiemetic prophylaxis was significantly more effective than the doublet in the overall (risk difference [RD]: 0.11, 95% confidence interval [CI]: 0.06-0.17) and delayed (RD: 0.08, 95% CI: 0.02-0.13) phases. For TC, no significant differences were observed in any phase. Adding NK1RA did not cause adverse events.ConclusionsAdding NK1RA to CBDCA-based chemotherapy has shown clinical benefits. However, the clinical benefits of NK1RA-containing regimens for overall MEC have not yet been established and require RCTs that exclusively evaluate MEC regimens other than CBDCA-based chemotherapy.

引用

页码：1616 / 1631

页数：16

共 50 条

[31] Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis
Ronald Chow
David G. Warr
Rudolph M. Navari
May Tsao
Marko Popovic
Leonard Chiu
Milica Milakovic
Henry Lam
Carlo DeAngelis
Supportive Care in Cancer, 2018, 26 : 2519 - 2549
[32] Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)
Aziz, Z.
Arpornwirat, W.
Herrstedt, J.
Camlett, I.
Piontek, T.
Ranganathan, S.
Schnyder, J.
Bandekar, R. R.
Levin, J.
Shaharyar, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[33] Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)
Grunberg, S. M.
Aziz, Z.
Shaharyar, A.
Herrstedt, J.
Roila, F.
VanBelle, S.
Bandekar, R. R.
Guckert, M. E.
Russo, M. W.
Arpornwirat, W.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[34] Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
Weinstein, Cindy
Jordan, Karin
Green, Stuart
Khanani, Saleem
Beckford-Brathwaite, Elizabeth
Vallejos, Waldimir
Pong, Annpey
Noga, Stephen J.
Rapoport, Bernardo L.
BMC CANCER, 2020, 20 (01)
[35] Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
Cindy Weinstein
Karin Jordan
Stuart Green
Saleem Khanani
Elizabeth Beckford-Brathwaite
Waldimir Vallejos
Annpey Pong
Stephen J. Noga
Bernardo L. Rapoport
BMC Cancer, 20
[36] Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC).
Arpornwirat, W.
Albert, I.
Hansen, V. L.
Russo, M. A.
Ross, G. A.
Pence, C. D.
Bandekar, R. R.
Grunberg, S. M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 471S - 471S
[37] The prophylactic use of Chinese herbal medicine for chemotherapy-induced leucopenia in oncology patients: a systematic review and meta-analysis of randomized clinical trials
L. X. Ma
P. Ai
H. Li
J. Vardy
Supportive Care in Cancer, 2015, 23 : 561 - 579
[38] The prophylactic use of Chinese herbal medicine for chemotherapy-induced leucopenia in oncology patients: a systematic review and meta-analysis of randomized clinical trials
Ma, L. X.
Ai, P.
Li, H.
Vardy, J.
SUPPORTIVE CARE IN CANCER, 2015, 23 (02) : 561 - 579
[39] Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials
Zhou, Jian-Guo
Huang, Lang
Jin, Su-Han
Xu, Cheng
Frey, Benjamin
Ma, Hu
Gaipl, Udo S.
ESMO OPEN, 2020, 5 (01)
[40] Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis
Tobias Engel Ayer Botrel
Otávio Augusto C. Clark
Luciana Clark
Luciano Paladini
Enéas Faleiros
Bruna Pegoretti
Supportive Care in Cancer, 2011, 19 : 823 - 832

← 1 2 3 4 5 →